Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1954 Jul;33(7):1047–1053. doi: 10.1172/JCI102972

STUDIES ON HYDRALAZINE; EVIDENCE FOR A PERIPHERAL SITE OF ACTION 1

Albert Stunkard 1,2,3,2, Lothar Wertheimer 1,2,3, Walter Redisch 1,2,3, Louisa Mulcare 1,2,3
PMCID: PMC438540  PMID: 13174662

Full text

PDF
1047

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CRAVER B. N., BARRETT W., CAMERON A., YONKMAN F. F. The activities of 1-hydrazinophthalazine (Ba-5968); a hypotensive agent. J Am Pharm Assoc Am Pharm Assoc. 1951 Nov;40(11):559–564. doi: 10.1002/jps.3030401109. [DOI] [PubMed] [Google Scholar]
  2. Chasis H., Ranges H. A., Goldring W., Smith H. W. THE CONTROL OF RENAL BLOOD FLOW AND GLOMERULAR FILTRATION IN NORMAL MAN. J Clin Invest. 1938 Sep;17(5):683–697. doi: 10.1172/JCI100996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. FREIS E. D., FINNERTY F. A., Jr Suppression of vasomotor reflexes in man following L-hydrazinophthalozine (C-5968). Proc Soc Exp Biol Med. 1950 Oct;75(1):23–24. doi: 10.3181/00379727-75-18085. [DOI] [PubMed] [Google Scholar]
  4. FREIS E. D., MacKAY J. C., OLIVER W. F. The effect of sympatholytic drugs on the cardiovascular responses to epinephrine and norepinephrine in man. Circulation. 1951 Feb;3(2):254–259. doi: 10.1161/01.cir.3.2.254. [DOI] [PubMed] [Google Scholar]
  5. GRIMSON K. S., ORGAIN E. S., ROWE C. R., Jr, SIEBER H. A. Caution with regard to use of hexamethonium and "apresoline". J Am Med Assoc. 1952 May 17;149(3):215–220. doi: 10.1001/jama.1952.02930200001001. [DOI] [PubMed] [Google Scholar]
  6. GROSS F., DRUEY J., MEIER R. Eine neue Gruppe blutdrucksenkender Substanzen von besonderem Wirkungscharakter. Experientia. 1950 Jan 15;6(1):19–21. doi: 10.1007/BF02154049. [DOI] [PubMed] [Google Scholar]
  7. MOYER J. H., HANDLEY C. A., HUGGINS R. A. Some pharmacodynamic effects of 1-hydrazinophthalazine (C-5968) with particular reference to renal function and cardiovascular response. J Pharmacol Exp Ther. 1951 Dec;103(4):368–376. [PubMed] [Google Scholar]
  8. REDISCH W., SHECKMAN E., STELLE J. M. Skin temperature response of normal human subjects to various conditions. Circulation. 1952 Dec;6(6):862–867. doi: 10.1161/01.cir.6.6.862. [DOI] [PubMed] [Google Scholar]
  9. REDISCH W., WERTHEIMER L., DELISLE C., STEELE J. M. Comparison of various vascular beds in man; their responses to a simple vasodilator stimulus. Circulation. 1954 Jan;9(1):63–67. doi: 10.1161/01.cir.9.1.63. [DOI] [PubMed] [Google Scholar]
  10. SCHROEDER N. A. The effect of 1-hydrasinophthalasine in hypertension. Circulation. 1952 Jan;5(1):28–37. doi: 10.1161/01.cir.5.1.28. [DOI] [PubMed] [Google Scholar]
  11. TAYLOR R. D., PAGE I. H., CORCORAN A. C. A hormonal neurogenic vasopressor mechanism. AMA Arch Intern Med. 1951 Jul;88(1):1–8. doi: 10.1001/archinte.1951.03810070011001. [DOI] [PubMed] [Google Scholar]
  12. WILKINSON E. L., BACKMAN H., HECHT H. H. Cardiovascular and renal adjustments to a hypotensive agent (l'hydrazinophthalazine: Ciba BA-5968: apresoline). J Clin Invest. 1952 Oct;31(10):872–879. doi: 10.1172/JCI102674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. YONKMAN F. F. Neurogenic hypertension; chemical approaches to its amelioration. J Mich State Med Soc. 1951 Feb;50(2):160–167. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES